Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
The 548-person U.S. study found that chronic hepatitis C infection occurred among an identical number of people who received the experimental vaccine compared to people who received a placebo.
Two models, one from Washington State and another from Los Angeles County, can be duplicated elsewhere to get people into care, experts say.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.
The data also reveals an estimated 2.3 million people living with HCV infection in the U.S. between 2013 and 2016, with a high burden in the West and in some Appalachian states.
Prior studies have indicated that hepatitis C direct-acting antivirals reduce the risk of hepatocellular carcinoma, but this is the first large prospective study to compare outcomes among treated and untreated patients.
Several new HIV/HCV coinfection resources for the HIV workforce were recently released by partners of the U.S. Department of Health and Human Services. Here's the department's quick roundup.
The number of people who inject drugs has soared, yet many drug patients are not checked for the virus that can damage the liver.
Reseearchers have discovered that very rare interferons, only found in hunter-gatherers from central Africa, are far better able to inhibit HCV infection.
One percent of the adult population in the U.S. were living with hepatitis C from 2013 through 2016, according to new estimates published by the Centers for Disease Control and Prevention.
On the surface, a 1.1 million drop in the prevalence of hepatitis C in the U.S. would seem to signal a major victory for the advances made in hepatitis C treatment this decade. But the reality is considerably more complex.